“Under the shadow of an Omicron catastrophe, the ever-evolving mutant(s) have adversely affected the vaccines and monoclonal antibody therapies substantially that were based upon immunity against the wild type virus. At the same time, mutant-based vaccines, due to manufacture and regulatory hurdles as well as the complex global distribution of different viral strains, will not be able to catch up in the real world.

                                              Emil Tsai, MD, PhD, CEO

Mission

SyneuRx’s mission is to bring breakthrough therapeutics to diseases and conditions where there are significant unmet needs, with a humanistic approach.

Value

Creativity, Integrity, Tenacity

Philosophy

  • “Value-based” drug development (not “me too” or “me-better”)
    • We aim to develop breakthrough therapies that bring the forefront of science to patients with real/meaningful value, rather than “me too” or “me-better” drugs that yields limited marginal benefits.
  • “Safety” first (not “efficacy” first)
    • We screen and select potential compounds are based on safety first, not efficacy. This is particularly important for the CNS pipeline due to the widespread presence of NMDA receptors in the brain and the potential neurotoxicity a misfit compound can induce.
  • “Human-health” focus (not just “patient-health”)
    • We aspire to promote “human-health” in addition to improving patient health individually. The development of potential treatment in schizophrenia, dementia, and depression can contribute to mental health parity. We would also make our potential new treatments available worldwide, eliminating inequity in health due to access.
    • We pledge to minimize the environmental impacts in all the steps of our R&D and commercialization processes, including green sourcing and manufacturing, minimizing toxic wastes, and green disposals.
    • People-centric work environment

Leadership Team

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

“The best science is what your grandmother can understand”

Major Milestone

Picture of 2022. 05
2022. 05

COVID MOA results published in ACS

2022.04

Pantalandir Phase 2 reached target enrollment.

Picture of 2022. 01
2022. 01

Pantalandir showed efficacy in preclinical studies.

Picture of 2021.08

2021.08

Pentarlandir® Phase II study (SNB011) in early and mild COVID-19 was initiated in the US.

Picture of 2020

2020

Phase 2 IND for Synxyrin®(SNA11) in treatment-resistant depression and suicidal symptoms was approved by the US FDA

Picture of 2020

2020

Phase 2b/3 studies in refractory schizophrenia and adult schizophrenia were initiated in Europe.

Picture of Published ACS

Published ACS

2019

US FDA approves SyneuRx’ Phase 2 IND application for Tannquilynne® (SND51) in dementia with psychosis.

Picture of Published ACS

Published ACS

2018

US FDA approves SyneuRx’ Phase 3 IND application for Synapsinae® (SNG12) in major depressive disorder and suicidal symptoms.

Picture of Published ACS

Published ACS

2017

SyneuRx initiates Phase 2b/3 studies (SND12 & SND13) in refractory schizophrenia and adult schizophrenia in the US.

Picture of 2016

2016

SyneuRx was listed in the Emerging Stock Market in Taipei Exchange and trades under the ticker “TT6575”.

Picture of 2016

2016

US FDA approves SyneuRx’ Phase 2b/3 IND application for NaBen® (SND14) in mild dementia.

Picture of 2015

2015

US FDA grants Breakthrough Therapy Designation to ClozaBen®(SND12) for refractory schizophrenia.

Picture of 2014

2014

US FDA grants Breakthrough Therapy Designation to NaBen®(SND13) for adult schizophrenia.

Picture of 2014

2014

SyneuRx initiates Phase 2b/3 study (SND11) in adolescent schizophrenia in the US.

Picture of Company Founded

Company Founded

2013 SyneuRx is founded by Emil Tsai, MD. PhD. MAS., UCLA Professor in Psychiatry.